Skip to main content
AU Proudly Based in Australia
Research Use Only | Lab Tested | Secure Checkout
contact@peptidesaustralia.com
HomePeptides
Cognitive SupportReproductive & Sexual HealthMuscle Growth & PerformanceWeight LossMetabolic SupportLongevity & Anti-AgingHealing & RecoveryLab Supplies
BundlesResearch Areas
Metabolic ResearchCognitive ResearchLongevity ResearchGrowth Hormone Secretagogue ResearchCosmetic & Skin ResearchLaboratory Quality Control
Quality
Quality AssuranceCertificate of AnalysisScientific Review ProcessEditorial PolicyAuthors & Reviewers
Resources
Research InsightsPeptide CalculatorPeptide GlossaryReferencesAbout Us
Contact
Tirzepatide
Certificate of Analysis Batch PA-0024 — 10mg
View COA
Research Grade Quality Independently Tested

Tirzepatide

≥ 99% (HPLC) CAS 2023788-19-2 C₂₂₅H₃₄₈N₄₈O₆₈ Verified Synthesis Batch COA Available

$119.99

Size / Strength

ADD TO CART
HPLC Verified
COA Included
Fast Dispatch
Discreet Shipping
100% Quality Guarantee

Every batch of Tirzepatide is independently third-party tested. 30-day money-back guarantee — no questions asked.

≥ 99% Purity Verified
HPLC Tested & Verified
Cold Chain Temperature Controlled
Next Day Fast & Discreet

Tirzepatide – Research Overview

Tirzepatide is a research-grade compound supplied for laboratory use only.

Research Use Only

This product is intended solely for laboratory research purposes. Not for human consumption.

Tirzepatide – Storage & Handling

Correct storage is essential for maintaining the stability and purity of Tirzepatide. Follow the guidance below for both the lyophilised (freeze-dried) powder and any reconstituted solution.

  • Store lyophilised powder at 2–8°C (refrigerated), protected from light
  • For longer-term storage, keep frozen at -20°C in the original sealed vial
  • Once reconstituted, refrigerate at 2–8°C and use within 30 days
  • Avoid repeated freeze-thaw cycles once reconstituted
  • Shelf life of 24 months from manufacture date when stored correctly

Tirzepatide – Technical Specifications

Every batch of Tirzepatide is independently analysed before dispatch. The values below describe the current research batch.

Product NameTirzepatide
CAS Number2023788-19-2
Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight4813.45 g/mol
Quantity / Strength10mg | 15mg | 30mg | 45mg | 60mg
Purity ≥ 99% (HPLC)
FormLyophilised Powder
AppearanceWhite Lyophilised Powder
Batch NumberPA-0024
Storage Conditions2°C-8°C (Refrigerated)
CategoryWeight Loss
Intended UseResearch Use Only — not for human consumption

Tirzepatide – Certificate of Analysis

Every batch of Tirzepatide is independently tested before dispatch. View the full COA for the current batch below.

Certificate of Analysis (COA)

Batch Number PA-0024

≥ 99% Purity HPLC
Confirmed Identity Mass Spec
Pass Heavy Metals ICP-MS

Research Disclaimer

For Research Use Only — Not for Human Consumption

This content is provided for educational, scientific and research-information purposes only. It does not provide medical advice, treatment recommendations or personal dosage instructions. Tirzepatide has been investigated extensively in preclinical and clinical research, but the regulatory status, safety, efficacy and approved uses of registered Tirzepatide medicines should not be attributed to unregistered or research-grade products.

  • Not for human or veterinary use
  • No claims are made regarding safety or efficacy in humans
  • Must be handled with appropriate laboratory safety equipment
  • Purchaser assumes all responsibility for legal, compliant use

References

5 sources
  1. 1
    Frias JP, Nauck MA, Van J, et al. Efficacy and Safety of LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes: A Randomised, Placebo-Controlled and Active Comparator-Controlled Phase 2 Trial. The Lancet. 2018;392(10160):2180-2193.PubMed: https://pubmed.ncbi.nlm.nih.gov/30293770/
  2. 2
    Rosenstock J, Wysham C, Frías JP, et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. The Lancet. 2021;398(10295):143-155.PubMed: https://pubmed.ncbi.nlm.nih.gov/34186022/
  3. 3
    Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515.PubMed: https://pubmed.ncbi.nlm.nih.gov/34170647/
  4. 4
    Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.PubMed: https://pubmed.ncbi.nlm.nih.gov/35658024/
  5. 5
    Australian Government, Therapeutic Goods Administration (TGA). Mounjaro (Tirzepatide): Australian Prescription Medicine Decision Summary. Therapeutic Goods Administration. 12 January 2023.TGA: https://www.tga.gov.au/resources/auspmd/mounjaro

Citations are provided for research reference and open in a new tab. Listing a study does not imply it evaluated this specific product.

Tirzepatide – Frequently Asked Questions

Researchers Also Purchase

Stay Updated with New Research
and Exclusive Offers

Subscribe to our newsletter for the latest product updates, research insights and exclusive promotions.

We respect your privacy. Unsubscribe anytime.

Why Researchers Choose Us

Research-Grade Quality. Trusted by Researchers Across Australia.

Learn About Our Quality
Discreet Packaging
Fast Australia-Wide Delivery
Expert Support
30-Day Money Back